XML 72 R44.htm IDEA: XBRL DOCUMENT
v3.3.1.900

License and Collaboration Agreements (Details) - USD ($) $ in Millions | 1 Months Ended | 12 Months Ended |  |
--- | --- | --- | --- | ---
Sep. 30, 2015 | Jul. 31, 2014 | Feb. 28, 2014 | Mar. 31, 2013 | Dec. 31, 2015 | Dec. 31, 2013 | Dec. 31, 2011 | Dec. 31, 2009 | Dec. 31, 2004 | Nov. 30, 2015 | Apr. 29, 2013
Respironics Agreement |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreements |  |  |  |  |  |  |  |  |  |  |
Aggregate payment upon the achievement of certain clinical milestones |  |  |  |  |  |  |  |  |  | $ 7.6 |
Eleison License Agreement |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreements |  |  |  |  |  |  |  |  |  |  |
License revenues |  |  |  |  |  |  | $ 1.0 |  |  |  |
Premacure License Agreement |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreements |  |  |  |  |  |  |  |  |  |  |
License revenues |  |  |  |  |  | $ 11.5 |  |  |  |  |
License purchase option price |  |  |  | $ 11.5 |  |  |  |  |  |  |
Proceeds from sale of license |  |  |  |  |  |  |  |  |  |  | $ 11.5
CFFT |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreements |  |  |  |  |  |  |  |  |  |  |
Compensation earned under research funding agreements with CFFT |  |  |  |  |  |  |  | $ 2.2 | $ 1.7 |  |
Royalty payable on approval of ARIKAYCE as commercialized drug |  |  |  |  | $ 13.4 |  |  |  |  |  |
Royalty payment period |  |  |  |  | 3 years |  |  |  |  |  |
Period for meeting sales milestones for additional royalty payments |  |  |  |  | 5 years |  |  |  |  |  |
Royalty payable on meeting certain sales milestones |  |  |  |  | $ 3.9 |  |  |  |  |  |
Therapure |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreements |  |  |  |  |  |  |  |  |  |  |
Initial term of contract manufacturing agreement |  |  | 5 years |  |  |  |  |  |  |  |
Period of each automatic renewal of contract manufacturing agreement |  |  | 2 years |  |  |  |  |  |  |  |
Written notice period required for termination of contract manufacturing agreement |  |  | 2 years |  |  |  |  |  |  |  |
Therapure | Minimum |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreements |  |  |  |  |  |  |  |  |  |  |
Advance notice period for termination of contract manufacturing agreement by the entity |  |  | 180 days |  |  |  |  |  |  |  |
PARI Agreement |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreements |  |  |  |  |  |  |  |  |  |  |
Initial term of contract manufacturing agreement |  | 15 years |  |  |  |  |  |  |  |  |
Additional term of contract manufacturing agreement |  | 5 years |  |  |  |  |  |  |  |  |
PARI Agreement | Minimum |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreements |  |  |  |  |  |  |  |  |  |  |
Written notice period required for termination of contract manufacturing agreement |  | 1 year |  |  |  |  |  |  |  |  |
Fill/Finish Agreement |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreements |  |  |  |  |  |  |  |  |  |  |
Minimum obligation | $ 2.7 |  |  |  |  |  |  |  |  |  |
Extension period | 2 years |  |  |  |  |  |  |  |  |  |
Period prior to expiration for extension | 1 year |  |  |  |  |  |  |  |  |  |

X
- Definition Amount of royalty payments if entity meets certain milestones under a research and development agreement. + References No definition available. + Details
Name: | insm_AdditionalRoyaltyGuaranteesCommitmentsAmount
Namespace Prefix: | insm_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Represents the additional extension period of contract manufacturing agreement. + References No definition available. + Details
Name: | insm_AdditionalTermOfContractManufacturingAgreement
Namespace Prefix: | insm_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the advance notice period for termination of contract manufacturing agreement by the entity. + References No definition available. + Details
Name: | insm_AdvanceNoticePeriodForTerminationOfContractManufacturingAgreementByTheEntity
Namespace Prefix: | insm_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the extension period under the terms of the agreement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + References No definition available. + Details
Name: | insm_CommercialServicesAgreementExtensionPeriod
Namespace Prefix: | insm_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the period prior to the expiration of the agreement in which an agreement for extension may be entered into upon mutual agreement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + References No definition available. + Details
Name: | insm_CommercialServicesAgreementExtensionPeriodPeriodPriorToExpirationForExtensionAgreement
Namespace Prefix: | insm_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the minimum obligation due under the terms of the agreement. + References No definition available. + Details
Name: | insm_CommercialServicesAgreementMinimumObligation
Namespace Prefix: | insm_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Represents the initial period of contract manufacturing agreement. + References No definition available. + Details
Name: | insm_InitialTermOfContractManufacturingAgreement
Namespace Prefix: | insm_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the option provided to the licensee to purchase a fully paid option for cash payment. + References No definition available. + Details
Name: | insm_OptionPriceForLicense
Namespace Prefix: | insm_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Aggregate payment upon the achievement of certain clinical milestones. + References No definition available. + Details
Name: | insm_PaymentsUponAchievementOfClinicalMilestonesAmount
Namespace Prefix: | insm_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Period for meeting sales milestones for additional royalty payments after the drug is commercialized. + References No definition available. + Details
Name: | insm_PeriodForMeetingSalesMilestonesForAdditionalRoyaltyPayments
Namespace Prefix: | insm_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the period of each automatic renewal of contract manufacturing agreement. + References No definition available. + Details
Name: | insm_PeriodOfEachAutomaticRenewalOfContractManufacturingAgreement
Namespace Prefix: | insm_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the amount received by the entity in sale of a fully paid license related to the entity's product(s). + References No definition available. + Details
Name: | insm_ProceedsFromSaleOfLicense
Namespace Prefix: | insm_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Period for royalty payments under a research and development agreement. + References No definition available. + Details
Name: | insm_RoyaltyPaymentPeriod
Namespace Prefix: | insm_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the written notice period required for termination of contract manufacturing agreement by either party. + References No definition available. + Details
Name: | insm_WrittenNoticePeriodForTerminationOfContractManufacturingAgreement
Namespace Prefix: | insm_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Revenue from multiple-deliverable arrangements that include licensing fees and services revenue. Licensing revenue is consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity. Services revenue may be derived by providing other, nonspecified, services during the reporting period. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1(d),(e)) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688 + Details
Name: | us-gaap_LicenseAndServicesRevenue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 730 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 730 -SubTopic 20 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380 + Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount the entity has committed to make for future royalty guarantees. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 928 -SubTopic 440 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6473578&loc=d3e63223-108013 + Details
Name: | us-gaap_RoyaltyGuaranteesCommitmentsAmount
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=insm_RespironicsAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=insm_EleisonPharmaceuticalsLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=insm_PremacureLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=insm_CysticFibrosisFoundationTherapeuticsIncCollaborationAgreementsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=insm_TherapureBiopharmaIncContractManufacturingAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RangeAxis=us-gaap_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=insm_PRIPharmaGmbhCommercializationAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=insm_CommercialFilVFinishServicesAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |